Prolixin Related Published Studies
Well-designed clinical trials related to Prolixin (Fluphenazine)
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. [2007.03.30]
A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. [2006.04]
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. [2005.07]
Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. [2005.01]
Well-designed clinical trials possibly related to Prolixin (Fluphenazine)
Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. [2006.09]
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. [2005.09.01]
Other research related to Prolixin (Fluphenazine)
Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. [2007.11]
Diphenyl diselenide decreases the prevalence of vacuous chewing movements induced by fluphenazine in rats. [2007.10]
Intracerebroventricular ethanol-induced conditioned place preferences are prevented by fluphenazine infusions into the nucleus accumbens of rats. [2007.04]
Oral fluphenazine versus placebo for schizophrenia. [2007.01.24]
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study. [2006.11.24]
Adverse extrapyramidal effects in four horse given fluphenazine decanoate. [2006.07.01]
Invited review: fluphenazine augments retinal oxidative stress. [2005.08]
Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. [2005.06]
Depot fluphenazine decanoate and enanthate for schizophrenia. [2005.01.25]
Other possibly related research studies
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population. [2007.01]
Risks versus benefits of different types of long-acting injectable antipsychotics. [2006]
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report. [2006.06]
Antipsychotics produce locomotor impairment in larval zebrafish. [2006.03]
Management of psychosis in Australian general practice. [2006.03]
Importance of oral glucose tolerance test in patient with schizophrenia. [2005.06]
Performance of diadochokinetic movements in schizophrenic patients. [2005.11.15]
Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. [2006.11]
Bait-delivered pimozide causes precocious embryo implantation in mink: a fertility control option for the exotic stoat? [2006]
Pharmacological management of Huntington's disease: an evidence-based review. [2006]
Pharmacotherapy of treatment-resistant combat-related posttraumatic stress disorder with psychotic features. [2006.06]
Penfluridol for schizophrenia. [2006.04.19]
The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. [2006.11]
Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. [2006.02]
Phenothiazines induce apoptosis in a B16 mouse melanoma cell line and attenuate in vivo melanoma tumor growth. [2006.01]
[Pharmacokinetic mechanisms underlying resistance in psychopharmacological treatment. The role of P-glycoprotein] [2005.11]
Antipsychotic drugs and QT prolongation. [2005.09]
Possible malignant neuroleptic syndrome that associated with hypothyroidism. [2005.06]
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. [2006.03]
All-Cause Treatment Discontinuation in Schizophrenia During Treatment With Olanzapine Relative to Other Antipsychotics: An Integrated Analysis. [2007.06]
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy. [2007.05]
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. [2007.04]
Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. [2007.07]
Factors related to antipsychotic oversupply among Central Texas Veterans. [2007.06]
Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. [2007.09.05]
Treatment compliance of outpatients with schizophrenia: patient's attitudes, demographic, clinical and therapeutic variables. [2008.03]
Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs. [2008.02]
The therapeutic alliance and family psychoeducation in the treatment of schizophrenia: an exploratory prospective change process study. [2008.06]
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. [2008.05.08]
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. [2008.03]
Typical and atypical antipsychotics--the misleading dichotomy. Results from the Working Group 'Drugs in Psychiatry' (AGATE). [2008]
Two-year rehospitalization rates of patients with newly diagnosed or chronic schizophrenia on atypical or typical antipsychotic drugs: retrospective cohort study. [2008.04]
Does dopamine still have a leading role in advanced Parkinson's disease after subthalamic stimulation? [2008]
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. [2008.03]
|
